Hylke Waalewijn

发表

Optimizing Pediatric Dosing Recommendations and Treatment Management of Antiretroviral Drugs Using Therapeutic Drug Monitoring Data in Children Living With HIV

A. Turkova, M. Penazzato, T. Cressey, 2019, Therapeutic drug monitoring.

ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing

J. Seeley, C. Giaquinto, O. Kobusingye, 2021, BMC Infectious Diseases.

Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021

O. Kirk, A. Winston, C. Marzolini, 2022, HIV medicine.

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

Ana C. Matos, C. Königs, C. Giaquinto, 2022, The lancet. HIV.

Adequate exposure of 50 mg dolutegravir in children weighing 20 to 40 kg outside of sub-Sahara Africa

A. V. van Rossum, C. Vermont, E. Svensson, 2022, AIDS (London).

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

Ana C. Matos, C. Königs, J. Seeley, 2022, The lancet. HIV.

Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

C. Giaquinto, H. Mujuru, D. Gibb, 2022, The lancet. HIV.

Use of WHO paediatric weight-band dosing in drug labels.

A. Colbers, Hylke Waalewijn, Tom G. Jacobs, 2021, The Lancet HIV.

First reported use of zidovudine for prevention of perinatal HIV transmission in a premature neonate on extra corporal membrane oxygenation.

M. Emonts, D. Burger, A. Colbers, 2018, AIDS.

Pharmacokinetic Data of Dolutegravir in Second-line Treatment of Children With Human Immunodeficiency Virus: Results From the CHAPAS4 Trial

V. Mulenga, D. Gibb, A. Szubert, 2023 .

First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial

V. Mulenga, D. Gibb, L. Wiesner, 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023

C. Marzolini, A. Calmy, K. van Bremen, 2023, HIV medicine.